Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Tonix Pharma Collaborates With Massachusetts General Hospital For TNX-1900 In Binge Eating Disorder

  • Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has announced an agreement with Massachusetts General Hospital to evaluate TNX-1900 (intranasal potentiated oxytocin) in a Phase 2 trial as a potential treatment for binge eating disorder. 
  • The Phase 2 clinical trial is expected to start in 2H of 2022.
  • TNX-1900 is also in development for the treatment of chronic migraine. It is expected to enter a Phase 2 potential pivotal clinical trial to prevent migraine headache in chronic migraineurs in 2H of 2022.
  • The planned investigator-initiated Phase 2 trial will be a randomized, double-blind, placebo-controlled study of 60 patients with binge eating disorder and obesity. 
  • Related: Tonix Pharma Inks Research Pact For Oxytocin In Eating Disorder.
  • The 8-week study will evaluate the efficacy and safety of TNX-1900 as a treatment for binge eating disorder and determine whether TNX-1900 reduces bingeing frequency and body weight in adults. 
  • TNX-1900 is based on a proprietary potentiated formulation of oxytocin and is currently being developed as a candidate for chronic migraine prophylaxis, insulin resistance treatment, and related conditions.
  • Price Action: TNXP shares are up 1.65% at $0.21 during the market session on the last check Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.